#Influenza and Other Respiratory Viruses Research #References (AMEDEO, August 22 '26)

 

BMC Pediatr

1. XIA Z, Zhang H, Xu S, Lin X, et al
   Changes in pediatric pneumonia incidence and pathogen spectrum before, during, and after the COVID-19 pandemic: an eight-year inpatient data analysis from a tertiary hospital in Fujian, China.
   BMC Pediatr. 2026;26:766.
   PubMed         Abstract available
   
   

   
   Cell

2. LI L, Yan XL, Wang HY, Zhou HY, et al
   Viral protease-initiated lytic cell death as a universal antiviral mRNA therapy.
   Cell. 2026;189:5396-5410.
   PubMed         Abstract available
   
   

   
   J Gen Virol

3. SHIM K, Choi JH, Hwang EH, Kim G, et al
   Dose-dependent effects of recombinant spike protein-based vaccination on SARS-CoV-2 evolutionary dynamics and the emergence of variants in hamster models.
   J Gen Virol. 2026;107:002314.
   PubMed         Abstract available
   
   
4. GRANSTAD S, Tonnessen R, Ytrehus B, Descamps S, et al
   Multiple introductions of highly pathogenic avian influenza viruses into the High Arctic: Svalbard and Jan Mayen, 2022-2025.
   J Gen Virol. 2026;107:002305.
   PubMed         Abstract available
   
   

   
   J Virol

5. XU J, Chan H-w, Yang R, Wu X-R, et al
   Nicotine and cotinine enhance SARS-CoV-2 entry through distinct but complementary mechanisms in human respiratory epithelial cells.
   J Virol. 2026 Jul 31:e0097126. doi: 10.1128/jvi.00971.
   PubMed         Abstract available
   
   
6. HE L, Su Y-WN, Zhang F, Moustafa IM, et al
   Recovery of proofreading-impaired SARS-CoV-2 reveals a mutator phenotype and an ExoN activity threshold for viability.
   J Virol. 2026 Jul 29:e0080926. doi: 10.1128/jvi.00809.
   PubMed         Abstract available
   
   
7. BEETON K, Case JB
   Respiratory mucosal vaccines for emerging viruses: promise and challenges.
   J Virol. 2026 Jul 23:e0174825. doi: 10.1128/jvi.01748.
   PubMed         Abstract available
   
   
8. ZHOU R, Yue M, Shen Q, Liu N, et al
   Glucagon-like peptide-1 receptor agonist prevents pulmonary fibrosis following acute COVID-19 infection associated with type 2 diabetes.
   J Virol. 2026 Jul 9:e0040126. doi: 10.1128/jvi.00401.
   PubMed         Abstract available
   
   
9. LAMICHHANE P, Yang L, Santos C, Park H-S, et al
   Live human metapneumovirus vaccine candidates attenuated by temperature sensitivity mutations from human respiratory syncytial virus.
   J Virol. 2026 Jul 6:e0069226. doi: 10.1128/jvi.00692.
   PubMed         Abstract available
   
   

   
   Pediatrics

10. HUANG YN, Chang CJ, Dai YL, Kung YH, et al
    Early Antiviral Therapy in Pediatric Outpatients and Risk of Influenza-Related Hospitalization.
    Pediatrics. 2026 Aug 17:e2025075020. doi: 10.1542/peds.2025-075020.
    PubMed         Abstract available
    
    
11. ANTOON JW, Edwards KM
    Why Not Antivirals? Reconsidering Influenza Treatment in Children.
    Pediatrics. 2026 Aug 17:e2026076953. doi: 10.1542/peds.2026-076953.
    PubMed        
    
    

    
    PLoS Comput Biol

12. KRAMER SC, Pirikahu S, Kussmaul C, Opatowski L, et al
    The limitations of non-mechanistic methods for characterizing pathogen-pathogen interactions: A simulation study.
    PLoS Comput Biol. 2026;22:e1013859.
    PubMed         Abstract available
    
    
13. DIMITRIOU PA, D'Alessandro M, Chang BL, Silvestros V, et al
    Non-Markovian dynamics and effective reproduction number in COVID-19: Evidence from Cyprus contact tracing data.
    PLoS Comput Biol. 2026;22:e1014578.
    PubMed         Abstract available
    
    

    
    PLoS Med

14. KAMTCHUM-TATUENE J, Farrell J, Nolan J, Lessels S, et al
    Time trends in stroke incidence and modifiable risk factor prevalence in England (2018-2024): A record linkage population-based study.
    PLoS Med. 2026;23:e1004999.
    PubMed         Abstract available
    
    

    
    PLoS One

15. DI CHIARA C, Piche-Renaud PP, Rigamonti V, Cantarutti A, et al
    Pediatricians' attitudes and knowledge of RSV immunization products: A multi-country cross-sectional survey.
    PLoS One. 2026;21:e0356233.
    PubMed         Abstract available
    
    
16. APONTE-HAO S, Luu H, Martins KJB, Randall JR, et al
    Factors associated with severe COVID-19 outcomes among adults with at least a primary vaccination schedule: A retrospective cohort study from Alberta, Canada.
    PLoS One. 2026;21:e0354822.
    PubMed         Abstract available
    
    
17. SHANKER N, Reckling S, Snyder NL, Enright D, et al
    Addressing gaps in surveillance: Use of emergency department accessibility and social vulnerability to identify potential wastewater surveillance sites in North Carolina.
    PLoS One. 2026;21:e0346668.
    PubMed         Abstract available
    
    
18. KOSINSKA-SELBI B, Kowalczyk J, Pierscinska J, Weleszczuk J, et al
    Comprehensive and innovative post-market surveillance system for atypical respiratory pathogens detecting qPCR panel.
    PLoS One. 2026;21:e0349967.
    PubMed         Abstract available
    
    
19. D'SOUZA-RUSHTON GC, Seshu U, Blumberger L, Mazhar L, et al
    The CDC's management and COVID-19 vaccine recommendations during the COVID-19 pandemic: A healthcare worker's perspective.
    PLoS One. 2026;21:e0354686.
    PubMed         Abstract available
    
    
20. MOSSOP B, Choudhury S
    Regime-aware causal Bayesian forecasting for non-stationary time series.
    PLoS One. 2026;21:e0356474.
    PubMed         Abstract available
    
    
21. HUNG LF, Guo PX, Hou CY, Kuo YH, et al
    Changes in multidrug-resistant Enterobacteriaceae features among patients in the emergency room during the COVID-19 Omicron variant pandemic.
    PLoS One. 2026;21:e0355725.
    PubMed         Abstract available
    
    
22. 
    Correction: The interaction of RNA G-quadruplexes from the influenza A virus vRNA with TMPyP4 and BRACO-19 ligands.
    PLoS One. 2026;21:e0356274.
    PubMed         Abstract available
    
    

    
    Vaccine

23. TANI N, Sato T, Goto T, Harada Y, et al
    Longitudinal changes in the antibody responses and adverse reactions across successive SARS-CoV-2 mRNA vaccinations from the primary series to the JN.1-adapted booster in hospital employees: A 4-year prospective cohort study.
    Vaccine. 2026;89:128887.
    PubMed         Abstract available
    
    
24. EZEJA L, Ezeala OM, Westrick SC, Qian J, et al
    Adverse events and vaccine administration errors following RSV vaccination: Findings from the United States VAERS database, 2023-2025.
    Vaccine. 2026;89:128896.
    PubMed         Abstract available
    
    
25. LIU STH, Gonzalez-Dominguez I, Martinez-Perez A, Bozkus CC, et al
    Phase 1 trial of intranasal NDV-HXP-S in previously vaccinated adults.
    Vaccine. 2026;89:128870.
    PubMed         Abstract available
    
    
26. KAUTZ A, Yang DH, Chickery S, Irving SA, et al
    Influence of correlated vaccination behaviors on estimates of COVID-19 vaccine effectiveness in older adults - VISION network, October 2023 - March 2024.
    Vaccine. 2026;89:128891.
    PubMed         Abstract available
    
    
27. BROWN J, Brennan H, Levine CB, Gwynn L, et al
    A historical overview of the anti-vaccine movement and its public health implications.
    Vaccine. 2026;89:128903.
    PubMed         Abstract available
    
    
28. DEPICKERE S, Pannus P, Houben S, Charles A, et al
    Safety and immunogenicity of a reduced, homologous booster dose of the BNT162b2 mRNA COVID-19 vaccine: a single blind, randomized, non-inferiority follow-up trial.
    Vaccine. 2026;89:128897.
    PubMed         Abstract available
    
    
29. KANDULU CC, Fleming A, O'Mahony A, McHugh S, et al
    Barriers and facilitators to COVID-19 vaccination programme implementation in Ireland: a qualitative study of implementation stakeholders using CFIR.
    Vaccine. 2026;89:128909.
    PubMed         Abstract available
    
    
30. WILLIAMS J, Degeling C, Donovan L, Wiley K, et al
    Australians' attitudes to mRNA vaccination in humans and animals: A cross-sectional survey.
    Vaccine. 2026;89:128907.
    PubMed         Abstract available
    
    
31. SANDERS JG, Kroese F, Mehra S, Stok M, et al
    Switching the default: a formative evaluation of pre-booked appointments on COVID-19 vaccination uptake and effects on intended uptake.
    Vaccine. 2026;89:128967.
    PubMed         Abstract available
    
    
32. MAZIBUKO L, Hoor D, Nxumalo V, Nxumalo S, et al
    The association of individual, interpersonal and social support factors with willingness to vaccinate against COVID-19 in rural South Africa.
    Vaccine. 2026;89:128998.
    PubMed         Abstract available
    
    
33. AUGUSTO LV, de Araujo LP, Silva EN, Gutierres JM, et al
    Intersection of vaccination, health literacy, education, and communication in South America: A scientometric mapping.
    Vaccine. 2026;89:128986.
    PubMed         Abstract available
    
    
34. SUZUKI Y, Arita T, Shirakura M, Kishida N, et al
    A novel candidate vaccine virus derived from Japan's first mammalian case of clade 2.3.4.4b A/H5N1 highly pathogenic avian influenza virus.
    Vaccine. 2026;91:129048.
    PubMed         Abstract available
    
    
35. DHANDA S, Morris DE, Morton K, Hazell L, et al
    Enhanced passive safety surveillance (EPSS) of a seasonal intranasal influenza vaccine (Fluenz(R) Tetra) in children in England: methodology, results and lessons learned from eight influenza seasons (2015/2016 to 2022/2023).
    Vaccine. 2026;91:129007.
    PubMed         Abstract available
    
    
36. HERMANN E, Krammer F
    The return of H1N1: Reemergence of the influenza virus A subtype H1N1 in 1977.
    Vaccine. 2026;91:128963.
    PubMed         Abstract available